Baird analyst Brian Skorney said the Amgen (AMGN) acquisition of Horizon Therapeutics (HZNP) yields some nice near term accretion but the sizeable debt position and bidding war keeps him cautious. He said the company will be sitting on one of the largest debt positions in the sector and with competitors all bowing out of the process, the deal may be more optical benefit on EPS than positive ROI. Skorney maintains his Underperform rating and $185 price target on Amgen shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AMGN:
- Mirati (NASDAQ:MRTX) Stock Jumps as FDA Approves Lung Cancer Drug
- AMGEN ANNOUNCES 10% INCREASE IN 2023 FIRST QUARTER DIVIDEND
- Amgen raises quarterly dividend by 10% to $2.13
- Amgen price target raised to $299 from $297 at Piper Sandler
- Horizon Therapeutics downgraded to Equal Weight from Overweight at Wells Fargpo